Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis

Table 2 Baseline clinical and demographic patient characteristics

	Patients with CRSwNP (n = 17)	Patients without CRSwNP (n = 106)	p value
Age (years)	51.6 ± 12.5	52.9 ± 13.7	0.626
Female (%)	58.8	62.3	0.786
BMI (kg/m²)	24.8 ± 4.1	26.4 ± 4.8	0.155
Time from asthma diagnosis (years)	12.9 ± 9.9	18.6 ± 14.0	0.161
FEV₁ (l)	1.74 ± 0.80	1.70 ± 0.72	0.735
FEV₁ % predicted, median (Q1–Q3)	61.01 (48.53–70.58)	54.18 (45.65–69.23)	0.690
ACQ	2.87 ± 1.60	2.98 ± 1.02	0.706
No. of asthma exacerbations in the previous 12 months	5.13 ± 4.13	4.54 ± 4.08	0.413
Monthly dose of omalizumab, mg	553.13 ± 303.57	521.23 ± 331.68	0.5233

Data are mean ± SD unless otherwise stated
ACQ Asthma Control Questionnaire, BMI body mass index, FEV₁ forced expiratory volume in 1 s, CRSwNP chronic rhinosinusitis with nasal polyps, SD standard deviation

ISSN: 2045-7022